Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: Effects on left-ventricular function, inflammatory cytokines and symptoms

European Journal of Heart Failure

Volumn 6, Issue 2, 2004, Pages 195-201

  Bahrmann, Philipp ^a   Hengst, Uta M ^a   Richartz, Babara M ^a   Figulla, Hans R ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cardiomyopathy; Cytokines; Ejection fraction; Heart failure treatment; Pentoxifylline

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 6; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

CARDIOMYOPATHY, DILATED; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PENTOXIFYLLINE; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 1342324113     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.09.005     Document Type: Article

References (29)

1. Cleland J.G.F. Heart failure: a medical hydra. Lancet. 352:(Suppl):1998;1-2.
2. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med. 323:1990;236-241.
3. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Rev Chest. 105:1994;897-904.
4. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunctions (SOLVD). J Am Coll Cardiol. 27/5:1996;1201-1206.
5. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factors in failing human heart. Circulation. 93/4:1996;704-711.
6. Seta Y., Shan K., Bozkurt B., Oral H., Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure. 2:1996;243-249.
7. Bolger A.P., Anker S.D. Tumor necrosis factor in chronic heart failure. Drugs. 60:2000;1245-1257.
8. Dispersyn G.D., Borgers M. Apoptosis in the heart: about programmed cell death and survival. News Physiol Sci. 16:2001;41-47.
9. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 91:2002;988-998.
10. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 99:1999;3224-3226.
11. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 103:2001;1044-1047.
12. Kelly R.A., Smith T.W. Cytokines and cardiac contractile function. Circulation. 95:1997;778-781.
13. Belloc F., Jaloustre C., Dumain P., Lacombe F., Lenoble M., Boisseau M.R. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol. 25:(Suppl. 2):1995;S71-S74.
14. Waage A., Sorensen M., Stordal B. Differential effects of pentoxifylline on tumor necoris factor and interleukin-6 production. Lancet. 335:1990;543.
15. Zabel P., Wolter D.T., Schonharting M.M., et al. Oxpentifylline in endotoxaemia. Lancet. 2:1989;1474-1477.
16. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093.
17. Skudicky D., Sliwa K., Bergemann A., Candy G., Sareli P. Reduction in Fas/Apo-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart. 84:2000;438-441.
18. Skudicky D., Bergemann A., Sliwa K., Candy G., Sareli P. Benefical effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation. 103:2001;1083-1088.
19. Sliwa K., Woodiwiss A., Candy G., et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 90:2002;1118-1122.
20. Barnett J.C., Touchon R.C. Therapy of ischemic cardiomyopathy with pentoxifylline. Angiology. 41:1990;1048-1052.
21. Rector T.S., Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 124:1992;1017-1025.
22. Wasserman K., Hansen J.E., Sue D.Y., Casaburi R., Whipp B.J. Principles of exercise testing and interpretation. 3rd ed. 1999;Lippincott, Williams and Wilkins, Philadelphia.
23. Sliwa K., Skudicky D., Candy G., Bergemann A., Hopley M., Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Failure. 4:2002;305-309.
24. Gullestad L., Aukrust P., Ueland T., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 34:1999;2061-2067.
25. Prabhu S.D., Chandrasekar B., Murray D.R., Freeman G.L. β-adrenergic blockade in developing heart failure. Circulation. 101:2000;2103-2109.
26. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 28:1996;964-971.
27. Müller-Werdan U., Schumann H., Loppnow H., et al. Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyoctes, but have different cardio-depressant profiles. J Mol Cell Cardiol. 30:1998;1027-1036.
28. Clerico A., Jervasi G., Del Chicca M.G., et al. Circulating levels of cardiac naturetic peptide (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 21:1998;170-179.
29. Marantz P.R., Tobin J.N., Wassertheil-Smoller S., et al. The relationship between left-ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 77:1998;607-612.